Pacira Pharmaceuticals Stock Price Prediction
| PCRX Stock | USD 25.90 0.91 3.39% |
Oversold Vs Overbought
38
Oversold | Overbought |
Pacira Pharmaceuticals stock price prediction is an act of determining the future value of Pacira Pharmaceuticals shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Pacira Pharmaceuticals' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Pacira Pharmaceuticals and does not consider all of the tangible or intangible factors available from Pacira Pharmaceuticals' fundamental data. We analyze noise-free headlines and recent hype associated with Pacira Pharmaceuticals, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Pacira Pharmaceuticals' stock price prediction:Quarterly Earnings Growth 0.291 | EPS Estimate Next Quarter 0.74 | EPS Estimate Current Year 2.78 | EPS Estimate Next Year 3.56 | Wall Street Target Price 46.4 |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Pacira Pharmaceuticals based on different types of headlines from major news networks to social media. The Pacira stock price prediction module provides an analysis of price elasticity to changes in media outlook on Pacira Pharmaceuticals over a specific investment horizon. Using Pacira Pharmaceuticals hype-based prediction, you can estimate the value of Pacira Pharmaceuticals from the perspective of Pacira Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Pacira Pharmaceuticals using Pacira Pharmaceuticals' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Pacira using crowd psychology based on the activity and movement of Pacira Pharmaceuticals' stock price.
Pacira Pharmaceuticals Short Interest
A significant increase or decrease in Pacira Pharmaceuticals' short interest from the previous month could be a good indicator of investor sentiment towards Pacira. Short interest can provide insight into the potential direction of Pacira Pharmaceuticals stock and how bullish or bearish investors feel about the market overall. An investor who is long Pacira Pharmaceuticals may also wish to track short interest. As short interest increases, investors should be becoming more worried about Pacira Pharmaceuticals and may potentially protect profits, hedge Pacira Pharmaceuticals with its derivative instruments, or be ready for some potential downside.
200 Day MA 31.5027 | Short Percent 0.1119 | Short Ratio 7.15 | Shares Short Prior Month 4.1 M | 50 Day MA 28.9322 |
Pacira Pharmaceuticals Hype to Price Pattern
Investor biases related to Pacira Pharmaceuticals' public news can be used to forecast risks associated with an investment in Pacira. The trend in average sentiment can be used to explain how an investor holding Pacira can time the market purely based on public headlines and social activities around Pacira Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Pacira Pharmaceuticals' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Pacira Pharmaceuticals.
Pacira Pharmaceuticals Implied Volatility | 58.35 |
Pacira Pharmaceuticals' implied volatility exposes the market's sentiment of Pacira Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Pacira Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Pacira Pharmaceuticals stock will not fluctuate a lot when Pacira Pharmaceuticals' options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in Pacira Pharmaceuticals. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Pacira Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Pacira because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Pacira Pharmaceuticals after-hype prediction price | USD 25.81 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Pacira contract
Based on the Rule 16, the options market is currently suggesting that Pacira Pharmaceuticals will have an average daily up or down price movement of about 3.65% per day over the life of the 2024-05-17 option contract. With Pacira Pharmaceuticals trading at USD 25.9, that is roughly USD 0.94 . If you think that the market is fully incorporating Pacira Pharmaceuticals' daily price movement you should consider acquiring Pacira Pharmaceuticals options at the current volatility level of 58.35%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Pacira |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Pacira Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Pacira Pharmaceuticals After-Hype Price Prediction Density Analysis
As far as predicting the price of Pacira Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Pacira Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Pacira Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Pacira Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Pacira Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Pacira Pharmaceuticals' historical news coverage. Pacira Pharmaceuticals' after-hype downside and upside margins for the prediction period are 23.68 and 27.94, respectively. We have considered Pacira Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Pacira Pharmaceuticals is very steady at this time. Analysis and calculation of next after-hype price of Pacira Pharmaceuticals is based on 3 months time horizon.
Pacira Pharmaceuticals Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Pacira Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pacira Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Pacira Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.32 | 2.15 | 0.09 | 0.09 | 7 Events / Month | 10 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
25.90 | 25.81 | 0.35 |
|
Pacira Pharmaceuticals Hype Timeline
Pacira Pharmaceuticals is at this time traded for 25.90. The entity has historical hype elasticity of -0.09, and average elasticity to hype of competition of 0.09. Pacira is projected to decline in value after the next headline, with the price expected to drop to 25.81. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.35%, whereas the daily expected return is at this time at -0.32%. The volatility of related hype on Pacira Pharmaceuticals is about 765.58%, with the expected price after the next announcement by competition of 25.99. About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.43. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pacira Pharmaceuticals had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in about 7 days. Check out Pacira Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Pacira Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Pacira Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Pacira Pharmaceuticals' future price movements. Getting to know how Pacira Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Pacira Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PAHC | Phibro Animal Health | (0.16) | 5 per month | 2.11 | 0.11 | 4.29 | (3.37) | 14.25 | |
| RDY | Dr Reddys Laboratories | 0.37 | 9 per month | 1.02 | (0.01) | 1.66 | (1.73) | 6.93 | |
| COLL | Collegium Pharmaceutical | 1.18 | 10 per month | 2.00 | 0.03 | 3.25 | (4.04) | 15.90 | |
| SSIC | Silver Spike Investment | (0.32) | 9 per month | 1.32 | 0.19 | 4.64 | (2.50) | 11.33 | |
| PBH | Prestige Brand Holdings | 0.92 | 11 per month | 0.84 | 0.12 | 2.03 | (1.96) | 11.76 | |
| HCM | HUTCHMED DRC | (0.07) | 11 per month | 3.32 | 0.09 | 8.15 | (5.55) | 23.25 | |
| IXHL | Incannex Healthcare Ltd | 0.37 | 7 per month | 0.00 | (0.03) | 14.10 | (15.80) | 75.54 | |
| EGRX | Eagle Pharmaceuticals | (0.40) | 10 per month | 4.87 | 0.03 | 8.00 | (7.92) | 23.10 | |
| ANIP | ANI Pharmaceuticals | 0.69 | 12 per month | 1.23 | 0.09 | 2.58 | (1.93) | 14.17 | |
| DCPH | Deciphera Pharmaceuticals LLC | (0.12) | 10 per month | 2.46 | 0.02 | 4.84 | (4.32) | 17.94 | |
| ITCI | Intracellular Th | 0.55 | 8 per month | 2.28 | 0.04 | 3.70 | (3.20) | 29.40 | |
| ALKS | Alkermes Plc | 0.36 | 10 per month | 0.00 | (0.09) | 2.79 | (4.24) | 21.89 |
Pacira Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Pacira price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Pacira using various technical indicators. When you analyze Pacira charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Pacira Pharmaceuticals Predictive Indicators
The successful prediction of Pacira Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Pacira Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Pacira Pharmaceuticals based on analysis of Pacira Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Pacira Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Pacira Pharmaceuticals's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Dividend Yield | 0.001004 | 0.001802 | 0.002073 | 0.001577 | Price To Sales Ratio | 4.92 | 2.64 | 2.31 | 2.19 |
Story Coverage note for Pacira Pharmaceuticals
The number of cover stories for Pacira Pharmaceuticals depends on current market conditions and Pacira Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Pacira Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Pacira Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
Pacira Pharmaceuticals Short Properties
Pacira Pharmaceuticals' future price predictability will typically decrease when Pacira Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Pacira Pharmaceuticals often depends not only on the future outlook of the potential Pacira Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Pacira Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 52 M | |
| Cash And Short Term Investments | 278.6 M |
Check out Pacira Pharmaceuticals Basic Forecasting Models to cross-verify your projections. For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Pacira Stock analysis
When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.291 | Earnings Share 0.89 | Revenue Per Share 14.603 | Quarterly Revenue Growth 0.054 | Return On Assets 0.0335 |
The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.